Otsuka Holdings completes acquisition of Transcend Therapeutics. Otsuka America will acquire 100 percent stake in the New York-listed biotech company for 700 million dollars upfront, with conditional milestone payments reaching up to 525 million dollars based on product sales. Transcend develops rapid-acting treatment products including TSND-201, led by Yale psychiatrist Dr. Benjamin Kelmendi. The company focuses on innovative therapies in mental health treatment. The acquisition awaits regulatory clearance. This strategic move expands Otsuka's presence in the psychiatric and neurological treatment space, positioning the company to commercialize cutting-edge rapid-acting therapeutics that address significant unmet medical needs in mental health care.
Post from MarketNews_en
Log in to interact with content.